News Room
News Room
News Room
Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa and [...]
Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
Expansion builds on initial strategic collaboration and license agreement Chicago, April 5, 2022 – Evozyne, Inc., an adaptive biology company [...]
Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation
License agreement secures potential research of ecopipam for one of the most common neurological sensory disorders Chicago, March 1, 2022 – Emalex Biosciences, Inc. [...]
Outstanding 2021 for Paragon Biosciences and Our Portfolio Companies
Chicago, Dec. 16, 2021 – Paragon Biosciences has had a stellar year of achievements in 2021, advancing our mission to solve some of society’s most [...]
PARAGON BIOSCIENCES EARNS 2021 GREAT PLACE TO WORK™ CERTIFICATION
Chicago, Dec. 7, 2021 – Paragon Biosciences is proud to announce that it has been certified as a Great Place to Work®. This prestigious [...]
Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome
Statistically significant, clinically meaningful results obtained on the primary and multiple secondary efficacy endpoints; ecopipam well tolerated in the study Chicago, Nov. 10, 2021 [...]
